Alirocumab reduces cardiovascular events after acute coronary syndrome
Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab reduced rates of major adverse cardiovascular events (MACE) ...
Mar 12, 2018
0
5